直接假体与分期组织扩张器乳房再造的成本与手术结局比较
该回顾性研究比较直接假体(DTI)与分期组织扩张器(TE)植入式乳房再造的全程诊疗费用与手术结局。DTI组主要并发症率更低(13%对22%,P=0.033),平均费用更低(13719.39±5499美元对16589.54±6586.95美元,P<0.001),手术费用与术后随访次数也更少。
要点
- DTI乳房再造全程费用显著低于分期TE再造。
- DTI主要并发症率更低,美学修整率无差异。
- TE组费用对脱细胞真皮基质使用最敏感。
核心结论
- DTI乳房再造在整个诊疗过程中的费用低于分期TE再造,主要因TE组计划手术费用和术后随访次数更多。
研究设计与样本
- 回顾性病历审查与机构财务部门特定费用数据分析,纳入205例患者(310侧乳房),DTI组167侧(54%),分期TE组143侧(46%)。
主要发现
- DTI组主要并发症率为13%,分期TE组为22%(P=0.033)。
- DTI组美学修整率为18%,分期TE组为19%(P=0.835)。
- DTI平均费用为13719.39±5499美元,分期TE为16589.54±6586.95美元(P<0.001)。
- DTI手术费用为10460.2±4059.81美元,分期TE为12242.87±4403.81美元(P=0.002)。
- DTI术后随访次数为13.27±7.76次,分期TE为23.03±9.05次(P<0.001)。
关键数值与推荐
- DTI再造费用对双侧手术率最敏感。
- 分期TE再造全程费用对脱细胞真皮基质的纳入最敏感。
- 并发症和美学修整的手术费用两组无差异。
临床怎么用
- 在植入式乳房再造决策中,可参考DTI费用更低且主要并发症更少的结果。
- TE再造时应关注脱细胞真皮基质使用对全程费用的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Implant-based breast reconstruction (IBBR) can be performed in a single stage (direct to implant [DTI]) or 2 stages using a tissue expander (TE). Fixed costs and postoperative complications can incur a significant financial burden. In this article, we compare direct costs of DTI to TE IBBR and determine price drivers to ascertain their relative costs. METHODS: A retrospective chart review and analysis of specific cost data provided by the authors' institutional finance department of patients who underwent IBBR was conducted to evaluate differences in costs during an episode of care (EOC). Multivariable regression analysis and 1-way sensitivity analysis were conducted to determine key price drivers for each operation. RESULTS: A total of 205 patients (310 breasts) undergoing DTI ( n = 167 [54%]) or staged TE ( n = 143 [46%]) reconstruction were evaluated over their entire EOC. The DTI cohort had a lower rate of major complications (13% versus 22%; P = 0.033) but similar rates of aesthetic revisions (18% versus 19%; P = 0.835). The average cost of a DTI reconstruction ($13,719.39 ± $5499) was significantly lower than for staged TE patients ($16,589.54 ± $6586.95; P < 0.001), with lower operative costs ($10,460.2 ± $4059.81 and $12,242.87 ± $4403.81; P = 0.002) and number of postoperative visits (13.27 ± 7.76 and 23.03 ± 9.05; P < 0.001). There were no differences in operative costs from complications and aesthetic revisions. The cost of a DTI reconstruction is most sensitive to the rate of bilateral operations. For staged TE reconstruction, the episodic cost is most sensitive to the incorporation of acellular dermal matrices. CONCLUSION: DTI breast reconstruction incurs lower cost over an EOC compared with staged TE reconstruction, because of greater planned operative costs and number of postoperative follow-ups in the TE group.
引用
- Chakraborty A, Bouhadana GC, Bernstein M, et al. Cost of Care and Surgical Outcomes between Direct-to-Implant and Staged Tissue Expander Breast Reconstruction. Plast Reconstr Surg. 2025. PMID: 41115310. doi:10.1097/PRS.0000000000012550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。